Procyanidin B2 prevents dyslipidemia via modulation of gut microbiome and related metabolites in high-fat diet fed mice

• Published in: Journal of functional foods Vol. 75; p. 104285
• Main Authors: Xiao, Ying, Yang, Changming, Xu, Haojie, Wu, Qiguo, Zhou, Yiming, Zhou, Xiaoli, Miao, Junli
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01-12-2020; Elsevier
• Subjects: Antioxidant; Dyslipidemia; Gut microbiome; Metabolomics; Procyanidin B2; PCoA; Metabolomics; PB2; RT; DG; HL; LDL-C; OTUs; compMW; Dyslipidemia; HFD; LPL; MDA; HDL-C; LC-MS/MS; SD; SMs; T-SOD; GSH; 16S rRNA; GSSG; PCs; GC–MS; CON; TCA cycle; OPLS-DA; AI; T-AOC; Antioxidant; TC; PCA; Procyanidin B2; TG; LysoPC; CoA; PE; CAT; SCFAs; VIP; Gut microbiome; HF
• ISSN: 1756-4646; 2214-9414
• DOI: 10.1016/j.jff.2020.104285

[Display omitted]
•Procyanidin B2 (PB2) prevents high-fat diet-induced dyslipidemia and LPL activity.•PB2 regulates gut microbiota and increase SCFAs content in dyslipidemia.•PB2 modulates twenty lipid metabolism biomarkers.•PB2 prevents dyslipidemia by reducing the abundance of Bilophila and Proteus.
This study aimed to elucidate the underlying mechanisms for the preventive effect of procyanidin B2 (PB2) on a high-fat diet (HFD)-induced dyslipidemia in C57BL/6 mice through a comprehensive analysis of fecal gut microbiome and plasma metabolomics. PB2 significantly reduced the levels of lipid metabolism biomarkers and increased the antioxidant abilities and lipoprotein lipase activity in mice fed with HFD (P < 0.05). Furthermore, the abundance of Blautia genus was increased, and that of Lachnoclostridium, Clostridium, Bilophila, Proteus genera were decreased in the PB2 group of mice compared to the HFD group of mice. Additionally, purine, unsaturated fatty acids, glycerophospholipids, and bile acids were up-regulated in the HFD fed mice plus PB2, and phenylglucuronide was down-regulated. The correlation analysis indicated that the gut microbiome, particularly Bilophila and Proteus genera, were strongly associated with the metabolic pathway modulation, which might have led to the preventive effect of PB2 on dyslipidemia.